Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class ...

Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), which is ...